



AJJ MEDTECH HOLDINGS LIMITED
(Company Registration No. 198403368H)
(Incorporated in the Republic of Singapore)

RESEARCH AND TECHNOLOGY PLATFORM DEVELOPMENT UPDATE RELATING TO THE RR-GOV™ GOVERNANCE READINESS FRAMEWORK AND RDIS FOR THE REGULATED DEPLOYMENT OF AI-ENABLED HUMANOID ELDERCARE ROBOTS

The board of directors (the “**Board**”) of AJJ Medtech Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce that Group’s Research Department has prepared a company-led research paper relating to the Group’s healthcare technology platform development initiatives, entitled:

“RR-Gov™: A Quantitative Governance Readiness Framework for Regulated Deployment of Embodied AI Eldercare Robotics — Toward an RDIS-Based Socio-Technical Systems Model for Assistive Robotics in the Health Domain”

The research paper relates to the Group’s continuing work in AI-enabled eldercare systems, embodied AI humanoid eldercare robotics, regulated deployment infrastructure, governance readiness, auditability, data governance and responsible institutional deployment assessment.

The research paper is intended to be made available as a company-led DOI-registered frontier systems technical paper and published on the Group’s corporate website Research page, for the purpose of establishing a public, traceable, citable and reviewable research record. The relevant DOI and website link are as follows:

Document Type: Company-led DOI-registered frontier systems technical paper

Status: Public research version; not independently peer-reviewed

DOI: 10.5281/zenodo.20815103, <https://zenodo.org/records/20815103>

Website: <https://www.ajjmedtech.com.sg/publication-2>

The Company will also publish a public-facing Q&A explanatory note on RR-Gov™ / RDIS on its corporate website to facilitate public understanding.

The first author of the research paper is **Mr Hon Hsiang Ong (William Ong)**, Chief Executive Officer of **AJJ Healthcare Management Pte. Ltd.**, the Group’s healthcare subsidiary. Based on the author contributions stated in the research paper, the work was jointly contributed to by AJJ Healthcare, relevant Group members and teams from the external technology collaboration partner, **Hangzhou Huaxi Intelligent Technology Co. Ltd.**, covering methodology, governance-framework development, institutional workflow interpretation, document review, evidence coordination, supplementary document organisation, original manuscript drafting, robotics deployment background, technical interpretation, application scenarios and related evidence support. Mr Ong’s participation as first author reflects the direct involvement of AJJ Healthcare’s management in governance-readiness research, institutional deployment planning and regulated deployment assessment relating to AI-enabled humanoid eldercare robots, while the joint participation of AJJ Healthcare, other Group members and the Huaxi team also reflects the Group’s continued investment and collaboration in healthcare technology platform development, application-scenario research for humanoid eldercare robots, governance-readiness assessment, data governance, evidence control, responsible deployment, talent development, talent application and cross-team research capability building.

1. Background

The Company believes that the responsible deployment of AI-enabled humanoid eldercare robots should not be evaluated solely by product functionality, mobility, interaction capability, monitoring support, fall-risk early warning and alert support for older persons, or their potential support capabilities in related care scenarios such

as Alzheimer’s disease and cognitive impairment care, late-life depression, anxiety, loneliness and psychosocial support, night-time sleep and bed-exit safety-risk support, hypertension and multimorbidity chronic care, long-term record-keeping and medication-adherence support. It also requires structured governance-readiness assessment covering human oversight, compliance readiness, auditability, data governance, institutional workflow integration and post-deployment monitoring.

In this context, RR-Gov™ is designed as a governance-readiness and institutional decision-support framework for assessing whether an embodied AI humanoid eldercare robot may be considered supportable for controlled institutional deployment under explicitly defined operating conditions and evidence boundaries.

2. Overview of the RR-Gov™ Framework and RDIS

The RR-Gov™ framework proposes a socio-technical governance-readiness assessment model for embodied AI humanoid eldercare robots. Its core output is the **Regulated Deployment Infrastructure Score (“RDIS”)**, a weighted composite candidate score supported by non-substitutable stage-gate thresholds, which assesses governance readiness across governance risk control, compliance confidence, AI auditability, institutional deployability, data governance and governance-adjusted viability.

The purpose of RR-Gov™ is not to determine whether a robot can perform isolated technical functions. Rather, it assesses whether the overall deployment system — including the robot, institution, staff workflow, data infrastructure, human oversight arrangements, audit trails and post-deployment feedback mechanisms — is sufficiently supported by governance evidence for controlled institutional deployment assessment. The stage-gate design is intended to prevent commercial, operational or adoption strengths from offsetting unresolved weaknesses in healthcare safety, compliance, auditability, data governance or human oversight; accordingly, a strong score in one area should not compensate for a critical weakness in another area involving older-person safety, healthcare safety, data protection, auditability or human oversight.

3. First-Definition-Type and Early Integrated Framework Positioning

Based on the Group’s public-source, academic, policy, standards, cross-language and negative-verification searches conducted to date, including the Group’s internal **RR-Gov™ / RDIS Prior Art, Public-Source and Literature Search Memorandum**, the Group has not identified a highly identical public integrated governance-readiness framework to RR-Gov™ / RDIS within the reviewed public-source scope. To the best of the Group’s knowledge, and subject to the limitations and evidence boundaries set out in the supporting memorandum, RR-Gov™ / RDIS may therefore be described as a **first-definition-type** and **among the earliest identified integrated governance-readiness assessment frameworks** for the regulated deployment of embodied AI humanoid eldercare robots.

The Group further considers that RR-Gov™ / RDIS may exhibit certain **world-first-characteristic features** within the currently identified public research landscape, particularly in combining an integrated weighted governance-readiness score, non-substitutable stage-gate logic, governance-card interpretation and regulated deployment infrastructure assessment for embodied AI humanoid eldercare robots. This positioning is intended to describe the Group’s research contribution and framework-setting direction, and should not be interpreted as a legally, regulatorily or academically conclusive claim of absolute global uniqueness, independent third-party validation, regulatory recognition or formal academic endorsement.

4. Public Research Status and Evidence Boundary

The RR-Gov™ research paper is a company-led research and technical framework document intended to support transparent research disclosure, public reference, governance discussion and subsequent scholarly development. It is not a peer-reviewed journal article as at the date of this announcement, and any future journal submission, peer review or academic publication will remain subject to the relevant journal’s editorial policies, peer-review process and publication decisions.

The research paper includes a demonstration assessment using anonymised and aggregated institutional evidence categories to illustrate how governance readiness may be translated into a weighted, auditable and stage-gated system-evidence model. Such demonstration result should be interpreted cautiously and should not be read as regulatory approval, clinical validation, medical-device classification, product certification, universal

safety proof, commercial endorsement or evidence of universal deployment readiness. Detailed formula definitions, scoring rubrics, evidence-control materials, calculation worksheets and monitoring templates may be retained in supplementary or internal governance materials for academic review, qualified review, governance reference and evidence-control purposes.

5. Strategic Relevance to the Group

The Company believes that the RR-Gov™ framework may support the Group's longer-term healthcare technology platform development by providing a structured governance-readiness language for AI-enabled humanoid eldercare robots, supporting engagement with institutions, regulators, healthcare operators, eldercare service providers and collaboration partners, and strengthening the Group's positioning in responsible AI, auditability, data governance, human oversight and healthcare safety.

It further believes that RR-Gov™ complements the broader research roadmap currently being advanced by the Group, including **RR-Care™**, **RR-Gov™**, **RR-Ethics™**, **HVCI2.3** and **research relating to the medical applications of humanoid eldercare robots**, by providing a governance reference basis for institutional pilot assessment, deployment-readiness review and responsible implementation planning. Such research work may also enhance the explainability, reviewability and external communication basis of the Group's healthcare technology platform, and provide a citable, traceable and scalable research foundation for more systematic engagement with healthcare and eldercare institutions, technology partners, academic parties, government-related stakeholders and potential investors.

6. Important Cautionary Statement

Shareholders and potential investors should note that this announcement and the RR-Gov™ research paper are intended as a research and technology platform development update only. They do not constitute or imply regulatory approval, clinical validation, medical-device or product certification, government or institutional endorsement, a commercial contract, sales or profit forecast, investment recommendation, product deployment readiness confirmation, or any assurance of future revenue, profitability, commercial adoption or financial performance.

The RR-Gov™ framework and RDIS model are research and governance-readiness assessment tools developed for structured discussion, institutional review, evidence-bounded interpretation and future scholarly development. Any future deployment, institutional adoption, regulatory interaction, commercial arrangement, clinical assessment or financial contribution will remain subject to separate evaluation, applicable laws and regulations, institutional requirements, regulatory processes, operational conditions, data-governance requirements and market conditions.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and should consult their professional advisers if in doubt.

BY ORDER OF THE BOARD

Dr Tan Wei Jie

Chief Executive Officer and Executive Director

Date: 01st July 2026

This document has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Centre, Singapore 068914.